Compare
Femasys Inc vs QHSLab, Inc. vs Vycor Medical Inc vs OSR Health, Inc.
| Latest fiscal year | Femasys Inc FEMY | QHSLab, Inc. USAQ | Vycor Medical Inc VYCO | OSR Health, Inc. OSRH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.29M | $2.69M | $1.86M | $2.91M |
| Revenue growth (YoY) | +40.8% | +26.3% | +17.2% | -17.7% |
| Gross margin | 62.0% (computed) | 67.3% | 83.8% | 20.4% |
| Operating margin | -767.0% | 4.9% | 1.8% | -631.0% |
| Net margin | -812.3% | 17.0% | -3.9% | -931.2% |
| Net income | -$18.63M | $457.4K | -$72.4K | -$27.06M |
| EPS (Diluted) | -$0.47 | $0.02 | -$0.01 | -$0.80 |
| Operating cash flow | -$18.69M | $178.1K | -$13.5K | -$4.33M |
| Free cash flow | -$19.22M | n/a | -$18.7K | n/a |
| Cash & equivalents | $9.27M | $636.2K | $87.0K | $1.70M |
| Total assets | $20.72M | $2.17M | $830.4K | $171.24M |
| Total liabilities | $14.85M | $546.1K | $4.92M | $44.20M |
| Shareholders' equity | $5.87M | $1.62M | -$4.09M | $127.04M |
| Return on year-end equity | -317.4% | 28.1% | n/a | -21.3% |
| Shares outstanding | 59.60M | 15.03M | 33.37M | 26.60M |
Revenue, most recent five fiscal years
| Fiscal year | Femasys Inc | QHSLab, Inc. | Vycor Medical Inc | OSR Health, Inc. |
|---|---|---|---|---|
| Latest | $2.29M Ended 2025-12-31 | $2.69M Ended 2025-12-31 | $1.86M Ended 2025-12-31 | $2.91M Ended 2025-12-31 |
| 1 year earlier | $1.63M Ended 2024-12-31 | $2.13M Ended 2024-12-31 | $1.59M Ended 2024-12-31 | $3.53M Ended 2024-12-31 |
| 2 years earlier | $1.07M Ended 2023-12-31 | $1.41M Ended 2023-12-31 | $1.46M Ended 2023-12-31 | n/a |
| 3 years earlier | $1.21M Ended 2022-12-31 | $1.24M Ended 2022-12-31 | $1.22M Ended 2022-12-31 | n/a |
| 4 years earlier | $1.18M Ended 2021-12-31 | $1.41M Ended 2021-12-31 | $1.39M Ended 2021-12-31 | n/a |